Seres Therapeutics, Inc. (MCRB)
- Previous Close
0.7600 - Open
0.7500 - Bid 0.7221 x 1600
- Ask 0.7582 x 1400
- Day's Range
0.6955 - 0.7858 - 52 Week Range
0.5400 - 6.6500 - Volume
5,803,543 - Avg. Volume
4,036,412 - Market Cap (intraday)
110.161M - Beta (5Y Monthly) 2.25
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8900 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.22
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
www.serestherapeutics.comRecent News: MCRB
Performance Overview: MCRB
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MCRB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MCRB
Valuation Measures
Market Cap
114.77M
Enterprise Value
200.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.77
Price/Book (mrq)
--
Enterprise Value/Revenue
1.59
Enterprise Value/EBITDA
-2.13
Financial Highlights
Profitability and Income Statement
Profit Margin
-90.03%
Return on Assets (ttm)
-19.08%
Return on Equity (ttm)
--
Revenue (ttm)
126.33M
Net Income Avi to Common (ttm)
-113.72M
Diluted EPS (ttm)
-0.8900
Balance Sheet and Cash Flow
Total Cash (mrq)
127.97M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-56.9M